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These results confirm the efficacy of ibuprofen,’ but do
not conform to the supposition of Bartsch and colleagues
that high-altitude headache might respond to stimulation of
5-HT, receptors by sumatriptan.2 Either their hypothesis is
wrong or different trial conditions are responsible for the
contrary results. In contrast to our investigation the
experiment of Bartsch and colleagues was not controlled and
therefore a placebo effect cannot be excluded. On the other
hand, their patients suffered from longer lasting and more
severe headache than those in our experiment. Based on the
speculation that severe headache causes an impaired blood-
brain barrier, a central site of action of sumatriptan could
explain the different effects observed.4 If sumatriptan acts
peripherally, we should have detected this. It remains to be
seen whether a new 5-HTj receptor agonist that penetrates
the blood-brain barrier more easily than sumatriptan will be
effective also for the treatment of less severe altitude
headache.’ 5
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Ibuprofen treatment of patent ductus
arteriosus
SIR In preterm infants patent ductus arteriosus (PDA) is a
common problem that leads to increased morbidity and
mortality. Conventional treatment with intravenous
indomethacin causes a decline in cerebral perfusion, reduced
mitochondrial oxygenation, and disruption of
cerebrovascular control.’,2 The risk of ischaemic injury after
indomethacin led a recent reviewer to stress the importance
of research into alternative drugs for use in newborn infants. 3
The action of indomethacin on PDA is mediated by
inhibition of prostaglandin synthesis,, but the deleterious
cerebral effects appear to be due to a different mechanism
which may be unique to indomethacin. We have therefore
studied the cerebral effects of a different prostaglandin
synthesis inhibitor, ibuprofen, in preterm infants born
between 23 and 28 (median 26) weeks postconceptional age.
The study compared the effects of ibuprofen 5 mg/kg
(n=12) or 10 mg/kg (n=6), with indomethacin 0-1 mg/kg
(n=15). The drugs were infused intravenously over 15
minutes during therapy for echocardiographically proven
PDA. Near infrared spectroscopy (NIRO 500,
Hammamatsu Photonics KK) was used to observe the effect
of treatment on cerebral perfusion, indicated by changes in
cerebral blood volume (CBV), and cerebral mitochondrial
oxygenation, determined by the change in concentration of
oxidised cytochrome aa3 ([Cyt02]). In six cases receiving
ibuprofen and four indomethacin, the response of CBV to
changes in arterial carbon dioxide tension (CBVR) was also
measured as an index of dynamic cerebrovascular control.
High and low doses of ibuprofen produced similar results,
with no significant change being detected: the median (25th
to 75th centiles) change in CBV was 0 (0-1 to -0-1)
mL/100 g; and in [Cyt02], 0 (0 to -0-1) &micro;mol/L. CBVR was
0-13 (0-10 to 0-21) mL 100 g-’ kPa-’ before and 0-16 (0-09
to 0-17) after treatment. Control injections of indomethacin,
on the other hand, induced significant falls in all variables
similar to those seen in previous studies: the change in CBV
was -0-4 (-0-3 to -0-5) mL/100 g; and in [CytO2], -0-2
(0 to -0-5) &micro;mol/L. CBVR fell from 0-17 (0-13 to 0-19) mL
100 g’’ kPa-’ before treatment to 0-06 (0-05 to 0-07). The
cerebral effects of ibuprofen and indomethacin were
significantly different (Kruskal-Wallis analysis of variance
with Dunn’s multiple comparison test, p<0001). However,
there was no apparent difference in rate of PDA closure:
both indomethacin and ibuprofen induced closure of the
PDA in 57% of treated infants.
Unlike indomethacin, ibuprofen appears to induce closure
of PDA without imparing cerebral haemodynamics and
oxygenation. These results suggest that indomethacin may
not be the best available drug for treating PDA in sick
preterm infants. They are also relevant to researchers
investigating the prophylactic administration of
prostaglandin synthase inhibitors to prevent periventricular
haemorrhage.
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Cutaneous dysplastic naevi: risk factor for
uveal melanoma
SIR-Many studies have looked at the phenotypic features of
individuals who are prone to develop cutaneous
melanoma. 1,2 One of the main factors in melanoma risk
assessment is the presence of dysplastic naevi (clinically
atypical moles).3
Risk factors for uveal melanoma are less well defined,
though Tucker et al4 observed that exposure to sunlight
increases the odds of intraocular malignant melanoma, and
atypical naevi are more common in uveal melanoma patients
than in controls.5
We have assessed the presence of dysplastic naevi among
75 consecutive uveal melanoma patients (36 women, 39
men; mean age 45-4 years) and 86 consecutive cutaneous
melanoma patients (47 women, 39 men; 47-3 years).
Controls were recruited from among patients referred to
other clinics (78 women, 65 men; 46-2 years).
Atypical naevi were found in greater proportions of the
uveal melanoma (17 of 75) and of cutaneous melanoma (19
of 86) groups than in the control group (9 of 143). The
relative risks of uveal melanoma and cutaneous melanoma
were 4-36 (95% CI 1-84-10-4) and 4-22 (1-81-9-84),
respectively.
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These results suggest that subjects with dysplastic naevi
are at similar risks of the development of uveal melanoma
and cutaneous melanoma, and that both dermatological and
ophthalmological follow-up is indicated.
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CD44v6 and CD44v3 expression in ulcerative
colitis and Crohn’s disease
SIR-Rosenberg and colleagues (May 13, p 1205) report
comparative expression of the v6 and v3 variants of CD44 in
ulcerative colitis, Crohn’s disease, and normal epithelium.
They describe immunohistochemical expression of CD44v6
in 23 of 25 patients with ulcerative colitis (with intensity of
immunostaining increasing with the severity of
inflammation), in three of 18 with Crohn’s colitis, and in
none of 22 with normal large bowel mucosa. Similarly there
was CD44v3 expression in all 16 patients with ulcerative
colitis as opposed to two of 11 with Crohn’s colitis and none
of 17 controls. They argue that such a consistent disease-
specific pattern of expression may indicate a role for these
molecules in the pathogenesis of ulcerative colitis. We agree
that a large body of evidence points to immune dysfunction
as an important factor in ulcerative colitis. Expression of
those molecules on epithelial cells that have corresponding
ligands on lymphocytes may be the first step in the initiation
of immune-mediated destruction by allowing lymphocyte-
epithelial adhesion. There are, however, several points that
we feel need further clarification. -
First, the same group, using the same antibodies, reported
weak but unequivocal expression of CD44v6 and CD44v3
in both formalin-fixed and frozen tissue from various normal
epithelia, including that of large bowel.’ We have also shown
CD44v6 expression in normal large bowel epithelium. How
do they reconcile this observation with their current finding
of no such expression of either of these molecules in normal
large bowel? Second, could the fact that the intensity of
immunostaining increased with the severity of inflammation
represent a disease-specific event rather than a primary
pathogenetic event? Third, they report that nine of 10
patients with dysplasia were positive for CD44v6. Was this
positivity in the presence of associated inflammation? If
immune surveillance of neoplastic tissue exists, one would
expect downregulation of those molecules involved in the
immune response.
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Authors’ reply
SIR-Ilyas and colleagues ask three questions. The first
addresses differences in the interpretation of weak positive
staining for CD44v3 and CD44v6 in large bowel biopsy
specimens, which may be semantic. In questioning
discrepancies between reports of weak staining with CD44
antibodies they identify the difficulty of comparing
subjective evaluations in different immunohistochemical
studies. Uncertainty about negative staining and degrees of
positivity can be reduced by including contemporaneous
controls which are treated and analysed identically to the
disease samples, use of a clearly described scoring system,
and by ensuring that observers are blinded to the clinical
diagnoses. Although these steps provide some degree of
objectivity within a single study, comparisons of levels of
staining between studies are subject to numerous errors,
especially in the absence of a standardised scoring system.
In our study we included biopsy specimens from healthy
controls and treated them identically to those from patients.
In the Patients and Methods section of our report, we
describe the scoring system that we used in reporting our
biopsy results, all of which were scored by observers blinded
to the clinical diagnoses. Fox et al,’ describe "weak focal
reactivity" with antibodies to CD44v3 and CD44v6 on
normal colorectal biopsy specimens, but do not describe the
scoring system used in reporting their results. The "weak
focal reactivity" described by Fox et al corresponds to
"patchy weak staining on fewer than 25% of crypt epithelial
cells per sample" graded as "negative" in our study.
We agree that the correlation between the intensity of
immunostaining and severity of inflammation in ulcerative
colitis may represent a disease-specific epiphenomenon.
However, CD44 v3 and v6 antibodies will still be of great
value in differentiating ulcerative colitis from other forms of
colonic inflammation if this observation proves to be disease
specific.
In the patients with dysplasia associated with ulcerative
colitis all the biopsy specimens showed mild to moderate
inflammation. It is our subjective impression that the pattern
of staining for CD44v6 in these specimens was more focal
than that seen in non-dysplastic samples, in line with the
suggestion that dysplastic cells are evading immune
surveillance. However, this observation needs verification.
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Swabaholics?
SIR-Liauw and Archer (June 24, p 1648) state that there is
no function to the use of alcohol-soaked swabs and that they
should therefore be abandoned. I have personally carried out
a single-user trial of my own use of alcohol swabs and find
that there are occasions when they are useful. It is well
known that some patients have good veins whereas others
are very difficult to bleed. If veins are prominent and easy to
see, I would agree with the assertion that there is very little
purpose in the use of alcohol swabs; however, when the
patients has bad veins, I find that alcohol swabs are
invaluable because they act as a lubricant which makes
palpation to find a suitable target more effective.
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